Andarix Pharmaceuticals Was Selected to Present at Lung Cancer Summit in Boston, MA

23:00 EDT 5 Aug 2017 |

Boston, MA, August 06, 2017 --( Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, recently presented at the Precision Lung Cancer Summit in Boston, Massachusetts July 25-26, 2017. Conference location and agenda information are available at the Precision Lung Cancer Conference.

“Lung cancer is the leading cause of death from cancer in the world and Andarix is committed to working with patients, providers and researchers to develop effective therapies to treat and eliminate the disease,” say Chris Adams, CEO of Andarix

About Tozaride
Tozaride is a novel, best-in-class therapy for lung and other cancers based on the radio-labeled somatostatin peptide Tozaride. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in heavily pre-treated advanced lung cancer patients. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC) patients, and which will provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.

About Andarix Pharmaceuticals
Andarix Pharmaceuticals is a clinical stage company developing targeted imaging and therapies for lung, neuroendocrine, and other cancers based on a proprietary somatostatin peptide conjugate. Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung cancers. Lung cancer is the leading cause of cancer mortality in the United States for both men and women. In 2013, there were an estimated 225,470 new diagnoses of non-small cell lung cancer (NSCLC) with 42,000 small cell lung cancer patients. To learn more about Andarix, please visit

Contact Information:
Chris Adams
Contact via Email

Read the full story here:

Press Release Distributed by

Original Article: Andarix Pharmaceuticals Was Selected to Present at Lung Cancer Summit in Boston, MA


More From BioPortfolio on "Andarix Pharmaceuticals Was Selected to Present at Lung Cancer Summit in Boston, MA"

Quick Search

Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...